Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Enanta Pharmaceuticals revenue
Enanta Pharmaceuticals's revenue is $67.6 million.
What is Enanta Pharmaceuticals's revenue?
- Enanta Pharmaceuticals's revenue growth from 2012 to 2024 is 62.17%.
- Enanta Pharmaceuticals has 155 employees, and the revenue per employee ratio is $436,354.
- Enanta Pharmaceuticals's peak quarterly revenue was $77.5M in 2015(q1).
- Enanta Pharmaceuticals peak revenue was $206.6M in 2018.
- Enanta Pharmaceuticals annual revenue for 2023 was 79.2M, -8.07% growth from 2022.
- Enanta Pharmaceuticals annual revenue for 2024 was 67.6M, -14.61% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Enanta Pharmaceuticals historical revenue
Enanta Pharmaceuticals's peak revenue was $206.6M in 2018. The peak quarterly revenue was $77.5M in 2015(q1).
Enanta Pharmaceuticals's revenue increased from $41.7m in 2012 to $67.6M currently. That's a 62.17% change in annual revenue.
Enanta Pharmaceuticals annual revenue
Enanta Pharmaceuticals annual revenue over time
| Fiscal year / year | Enanta Pharmaceuticals revenue |
|---|---|
| 2012 | $41.7M |
| 2013 | $32.1M |
| 2014 | $47.7M |
| 2015 | $160.9M |
| 2016 | $88.3M |
| 2017 | $102.8M |
| 2018 | $206.6M |
| 2019 | $205.2M |
| 2020 | $122.5M |
| 2021 | $97.1M |
| 2022 | $86.2M |
| 2023 | $79.2M |
| 2024 | $67.6M |
How accurately did Enanta Pharmaceuticals' revenue projections match actual performance?
Enanta Pharmaceuticals annual growth
Enanta Pharmaceuticals saw the greatest revenue growth in 2015, when revenue increased by 236.98%.
Enanta Pharmaceuticals had the lowest revenue growth in 2016, when revenue changed by -45.13%.
Enanta Pharmaceuticals annual growth rate over time
| Year | Enanta Pharmaceuticals growth |
|---|---|
| 2013 | -23%↓ |
| 2014 | 49%↑ |
| 2015 | 237%↑ |
| 2016 | -45%↓ |
| 2017 | 16%↑ |
| 2018 | 101%↑ |
| 2019 | -1%↓ |
| 2020 | -40%↓ |
| 2021 | -21%↓ |
| 2022 | -11%↓ |
| 2023 | -8%↓ |
| 2024 | -15%↓ |
Enanta Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Enanta Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $1.2M | $1.6M | $1.3M |
| 2014 | $893,000 | $2.2M | $42.1M | $2.6M |
| 2015 | $77.5M | $57.4M | $11.6M | $14.4M |
| 2016 | $48.4M | $13.0M | $14.0M | $12.8M |
| 2017 | $10.4M | $9.0M | $7.5M | $75.9M |
| 2018 | $38.1M | $44.0M | $57.3M | $67.2M |
| 2019 | $69.9M | $39.6M | $44.4M | $51.3M |
| 2020 | $52.6M | $27.6M | $18.7M | $23.6M |
| 2021 | $31.7M | $20.1M | $21.6M | $23.6M |
| 2022 | $27.6M | $18.7M | $19.5M | $20.3M |
| 2023 | $23.6M | $17.8M | $18.9M | $18.9M |
| 2024 | $18.0M | $17.1M | $18.0M | $14.6M |
| 2025 | $17.0M | - | - | - |
Enanta Pharmaceuticals jobs nearby
Do you work at Enanta Pharmaceuticals?
Is Enanta Pharmaceuticals transparent about its revenue structure?
Enanta Pharmaceuticals financial information
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 155 |
| Date Founded | 1995 |
| Headquarters | Watertown Town, Massachusetts |
| Number of Locations | 1 |
| Revenue | $67.6M |
| Net Income | -$133,816,000 |
| PE Ratio | -11.74 |
| Tax Rate | 0.0% |
| Market Capitalization | $1.4B |
| Total Assets | $462,275,000 |
| Ticker | ENTA |
Enanta Pharmaceuticals jobs you might like
Enanta Pharmaceuticals financing
Enanta Pharmaceuticals received early financing of $5.1M on 1999-01-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $5.1M | 01/1999 |
| Series B | $20M | 07/2000 |
| Series E | $18.3M | 07/2002 |
| Series Unknown | $12M | 01/2004 |
| Series Unknown | $20M | 08/2004 |
| Post Ipo Equity | $9.2M | 09/2013 |
Enanta Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Techno Venture Management | Series A |
| Techno Venture Management | Series B |
| Advent International | Series B |
| Oxford Bioscience Partners | Series B |
| Techno Venture Management | Series E |
| Advent International | Series E |
| Oxford Bioscience Partners | Series E |
| Bioventures Investors | Series Unknown |
| Techno Venture Management | Series Unknown |
| Advent International | Series Unknown |
| Wheatley MedTech Partners | Series Unknown |
| Yasuda Enterprise Development | Series Unknown |
| Oxford Bioscience Partners | Series Unknown |
| NIBC Bank | Series Unknown |
| Swiss Life Private Equity Partners | Series Unknown |
| Bioventures Investors | Series Unknown |
| Techno Venture Management | Series Unknown |
| Oxford Bioscience Partners | Series Unknown |
Enanta Pharmaceuticals competitors
Enanta Pharmaceuticals's top competitor, Alnylam Pharmaceuticals, earned an annual revenue of $2.2B.
Enanta Pharmaceuticals's smallest competitor is Cerexa Inc. with revenue of $1.3M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Aptuit | $66,558 | $100.0M | 1,733 | - |
| Rigel Pharmaceuticals | $83,403 | $179.3M | 158 | 6 |
| PTC Therapeutics | $92,986 | $806.8M | 517 | 21 |
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | 1 |
| Agios Pharmaceuticals | $84,094 | $94.4M | 536 | - |
| Forma Therapeutics | $79,424 | $100.6M | 103 | - |
| Tetraphase Pharmaceuticals | $70,421 | $7.4M | 67 | 3 |
| Aprecia Pharmaceuticals | $45,659 | $16.4M | 20 | 3 |
| Cerexa Inc. | $46,963 | $1.3M | 29 | - |
| Castle Biosciences | $84,006 | $332.1M | 200 | 29 |
Enanta Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Enanta Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Enanta Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Enanta Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Enanta Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Enanta Pharmaceuticals. The data presented on this page does not represent the view of Enanta Pharmaceuticals and its employees or that of Zippia.
Enanta Pharmaceuticals may also be known as or be related to ENANTA PHARMACEUTICALS INC, Enanta Pharmaceuticals, Enanta Pharmaceuticals Inc and Enanta Pharmaceuticals, Inc.